Ultragenyx exceeded 2024 revenue guidance, expects continued growth in 2025

From GlobeNewswire: 2025-01-12 11:00:00

Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2024 revenue results exceeding guidance, with total revenue of $555 million to $560 million. Revenue included Crysvita® revenue of $405 million to $410 million and Dojolvi® revenue of $87 million to $89 million. The company provided 2025 revenue guidance of $640 million to $670 million. Program updates include progress in the UX143 Phase 3 Orbit study for osteogenesis imperfecta and completion of enrollment in the GTX-102 Phase 3 Aspire study for Angelman syndrome by the second half of 2025.

In 2024, Ultragenyx Pharmaceutical Inc. saw substantial revenue growth and ended the year with approximately $745 million in cash, cash equivalents, and investments. The company expects 2025 revenues to grow by 14-20% compared to 2024. Key clinical milestones for 2025 include the progression of the UX143 Phase 3 Orbit study for osteogenesis imperfecta and the completion of enrollment in the GTX-102 Phase 3 Aspire study for Angelman syndrome. Additionally, a BLA submission for the DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia is expected in mid-2025.



Read more at GlobeNewswire: Ultragenyx Reports Preliminary 2024 Revenue, Financial